New Acute Lymphoblastic Leukemia Research Reported from University of Colorado Anschutz Medical Campus (Inhibiting Free Fatty Acid Transport to Improve CAR-T Cell Therapy of Relapsed B-Cell Acute Lymphoblastic Leukemia).

Researchers at the University of Colorado Anschutz Medical Campus have conducted a study on acute lymphoblastic leukemia (B-ALL) and its resistance to conventional chemotherapy. The research focused on the role of TP53 mutations in compromising the effectiveness of CD19-directed CAR-T cell therapy for relapsed B-ALL. They found that inhibiting free fatty acid transport, specifically targeting the FATP2 transporter, could potentially improve CAR-T therapy outcomes for B-ALL patients. This study sheds light on a potential metabolic vulnerability in B-ALL that could enhance the efficacy of CAR-T cell therapy. [Extracted from the article]